Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same
View Patent ↗Described herein are cannabidiol prodrugs, methods of making cannabidiol prodrugs, formulations comprising cannabidiol prodrugs and methods of using cannabidiols. One embodiment described herein relates to the transdermal or topical administration of a cannabidiol prodrug for treating and preventing diseases and/or disorders.
1. A compound selected from the group consisting of:
2. A pharmaceutical composition comprising:
(a) a compound as described in claim 1 ; and
(b) a pharmaceutically acceptable excipient.
3. A method of treating a medical condition in a mammal comprising the step of administering a compound as described in claim 1 , wherein the medical condition is selected from the group consisting of: nausea, vomiting, emesis, pain, wasting syndrome, HIV-wasting, chemotherapy induced nausea and vomiting, alcohol use disorders, dystonia, multiple sclerosis, inflammatory bowel disorders, arthritis, dermatitis, Rheumatoid arthritis, systemic lupus erythematosus, anti-inflammatory, anti-convulsant, anti-psychotic, anti-oxidant, neuroprotective, anti-cancer, immunomodulatory effects, peripheral neuropathic pain, neuropathic pain associated with post-herpetic neuralgia, diabetic neuropathy, shingles, burns, actinic keratosis, oral cavity sores and ulcers, post-episiotomy pain, psoriasis, pruritis, contact dermatitis, eczema, bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (e.g., Stevens-Johnson syndrome), seborrheic dermatitis, ankylosing spondylitis, psoriatic arthritis, Reiter's syndrome, gout, chondrocalcinosis, joint pain secondary to dysmenorrhea, fibromyalgia, musculoskeletal pain, neuropathic-postoperative complications, polymyositis, acute nonspecific tenosynovitis, bursitis, epicondylitis, post-traumatic osteoarthritis, synovitis, juvenile rheumatoid arthritis and inhibition of hair growth.
4. The method of claim 3 wherein the cannabidiol prodrug is administered transdermally.
5. The method of claim 3 wherein the cannabidiol prodrug is administered topically.
6. A method of administering a compound to a mammal comprising the steps of:
(a) combining a compound of claim 1 with a pharmaceutical excipient to form a pharmaceutical composition;
(b) creating a dosage form suitable for administration to a mammal from the pharmaceutical composition; and
(c) administering the dosage form to a mammal.
7. The method of claim 6 wherein the compound is administered by a route selected from the group consisting of: transdermal, topical, oral, buccal, sublingual, intra venous, intra muscular, vaginal, rectal, ocular, nasal and follicular.
8. The compound of claim 1 , which is:
9. The compound of claim 1 , which is:
10. The compound of claim 1 , which is:
11. The compound of claim 1 , which is:
12. The compound of claim 1 , which is:
13. The compound of claim 1 , which is:
14. The compound of claim 1 , which is:
15. The compound of claim 1 , which is:
16. The compound of claim 1 , which is:
17. The compound of claim 1 , which is:
18. The compound of claim 1 , which is:
19. The compound of claim 1 , which is:
20. The compound of claim 1 , which is:
21. The compound of claim 1 , which is:
22. The compound of claim 1 , which is:
23. The compound of claim 1 , which is:
24. The compound of claim 1 , which is:
25. The compound of claim 1 , which is:
26. The compound of claim 1 , which is: